|Articles|July 1, 2001

Applied Clinical Trials

  • Applied Clinical Trials-07-01-2001

ACT 101 Human Safety in Clinical Research

Pharmaceutical companies must pay close attention to the safety of human subjects at every stage of drug development, as explained in this QA view of the policies and regulations that make the system work.

Articles in this issue

over 25 years ago

Letters to the Editor

over 25 years ago

Conference Reports

over 25 years ago

Affairs of State

over 25 years ago

Pen-Based Computing

Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.